Skip to content
Menu

Ligand Pharmaceuticals Incorporated LGND

Full chart Compare
Set alert

Price alert · LGND

All alert types
286.85 USD -0.09 (-0.03%)

Regular-session close

286.85 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

283.01 Day range 291.33
181.65 52-week range 322.75
YTD
+51.72%
1 year
+44.12%

5D -20.93 (-6.75%)

290300310MonTueWedThuFri289.34
Market cap
5.74B
Revenue (ttm)
253.83M
Profit margin
20.27%
EPS (ttm)
2.49
Shares out
20.00M
P/E ratio
115.20
Forward P/E
24.00
YTD return
+51.72%
1-year return
+44.12%
50-day average
302.30
Volume
259.79K
Avg volume
229.12K
Open
285.21
Previous close
286.94
Day's range
283.01 – 291.33
52-week range
181.65 – 322.75
Beta
1.03
Analysts
Strong Buy
Price target
361.27 (+25.9%)
Earnings date
Feb 25, 2027

Key statistics

200-day average
260.34
Enterprise value
6.45B
PEG ratio
1.53
Price / sales
22.61
Price / book
5.97
Revenue growth
-31.80%
Free cash flow
62.45M
Total cash
447.40M
Total debt
1.15B
Return on equity
5.38%
Short % of float
14.76%

Fundamental scorecard

10 of 25 checks passed on LGND’s reported financials

ValueGrowthProfitabilityHealthDividend

10of 25 checks passed

  • Value 0 of 5
  • Growth 5 of 5
  • Profitability 3 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
LGND Revenue — quarterly 78.75M
LGND Net income — quarterly -28.48M
LGND EPS — quarterly -1.43

Earnings

LGND recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 20262.84———
Oct 29, 2026Sep 30, 20262.332.67+0.34+14.59%
Aug 6, 2026Jun 30, 20262.012.37+0.36+17.91%
May 14, 2026Mar 31, 20261.841.63-0.21-11.41%
Feb 26, 2026Dec 31, 20251.462.02+0.56+38.36%
Nov 6, 2025Sep 30, 20251.973.09+1.12+56.85%

Upgrades / downgrades

LGND analyst upgrades and downgrades
DateFirmActionFromTo
Nov 11, 2026BarclaysmainOverweightOverweight
Nov 5, 2026CitigroupmainBuyBuy
Oct 30, 2026RBC CapitalmainOutperformOutperform
Sep 25, 2026Barclaysinit—Overweight
Sep 24, 2026HC Wainwright & Co.reitBuyBuy
Sep 23, 2026CitigroupmainBuyBuy

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
ligand.com

News

Your note

Sign in to keep a note on LGND — it syncs with the Stock Master app.

Insider holders

LGND insider holders
InsiderRelationLatest transactionDateShares held
ARYEH JASON MDirectorSaleNov 9, 2026113,476
DAVIS TODD CLIFTONChief Executive OfficerStock Award(Grant)Mar 1, 2026199,381
ESPINOZA OCTAVIOChief Financial OfficerConversion of Exercise of derivative securityAug 11, 202627,696
GRAY NANCY RYANDirectorStock Award(Grant)Jun 4, 20268,930
HAAS JASONDirectorConversion of Exercise of derivative securityAug 11, 20263,981
KOZARICH JOHN W.DirectorSaleNov 11, 202642,122

Institution ownership

LGND institution ownership
Holder% heldSharesValueReported
Blackrock Inc.15.56%3,112,206892.74MSep 29, 2026
Invesco Ltd.7.52%1,503,709431.34MSep 29, 2026
Vanguard Portfolio Management LLC5.56%1,112,046318.99MSep 29, 2026
Janus Henderson Group Ltd.4.57%914,350262.28MSep 29, 2026
Franklin Templeton, Inc.4.56%912,311261.70MSep 29, 2026
Vanguard Capital Management LLC4.35%869,478249.41MSep 29, 2026

Fund ownership

LGND fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.94%1,187,510340.64MSep 29, 2026
AIM Counselor Series TRT -Invesco Discovery Fd.3.17%633,699181.78MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.03%605,720173.75MJun 29, 2026
Franklin Custodian Funds-FRANKLIN DYNATECH FUND2.75%550,000157.77MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.59%518,425148.71MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.18%436,817125.30MJun 29, 2026